Curcumin ameliorates DSS‑induced colitis in mice by regulating the Treg/Th17 signaling pathway

Wei, Cheng; Wang, Jianyao; Xiong, Feng; Wu, Ben-Hua; Luo, Ming‐Han; Yu, Zhichao; Liu, Tingting; Li, Defeng; Tang, Qi; Li, Yingxue; Zhang, Dingguo; Xu, Zefeng; Jin, Hongtao; Wang, Lisheng; Yao, Jun

doi:10.3892/mmr.2020.11672

Cited by 32 publications

(22 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, no considerable changes were observed in HIF1A between the colitis group and the curcumin group. Collectively, the results suggest that curcumin can treat colitis by regulating the re-equilibration of Treg/Th17 and that the regulatory mechanism could be associated with the IL‑23/Th17 pathway [ 97 ]. The details of in vitro and animal studies of curcumin administration in IBD treatment are presented in Table 3 .…”

Section: Curcumin In Inflammatory Bowel Diseasementioning

confidence: 99%

Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disorder of the small intestine and colon. IBD includes ulcerative colitis (UC) and Crohn’s disease (CD), and it is a major factor for the development of colon cancer, referred to as colitis-associated cancer (CAC). The current treatment of IBD mainly includes the use of synthetic drugs and monoclonal antibodies. However, these drugs have side effects over long-term use, and the high relapse rate restricts their application. In the recent past, many studies had witnessed a surge in applying plant-derived products to manage various diseases, including IBD. Curcumin is a bioactive component derived from a rhizome of turmeric (Curcuma longa). Numerous in vitro and in vivo studies show that curcumin may interact with many cellular targets (NF-κB, JAKs/STATs, MAPKs, TNF-γ, IL-6, PPARγ, and TRPV1) and effectively reduce the progression of IBD with promising results. Thus, curcumin is a potential therapeutic agent for patients with IBD once it significantly decreases clinical relapse in patients with quiescent IBD. This review aims to summarize recent advances and provide a comprehensive picture of curcumin’s effectiveness in IBD and offer our view on future research on curcumin in IBD treatment.

show abstract

Section: Curcumin In Inflammatory Bowel Diseasementioning

confidence: 99%

Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At present, many researches have proved that curcumin is safe and effective through DBPC test ( Heger, 2017 ). Curcumin may not fit medical chemists’ definition of the perfect drug, but many in vitro , in vivo and clinical trials have irrefutably confirmed its medicinal potential ( Li et al, 2015 ; Beloqui et al, 2016 ; Yang et al, 2018 ; Yue et al, 2019 ; Wei et al, 2021 ). We searched ClinicalTrials.gov to identify current clinical trials evaluating curcumin treatment for IBD.…”

Section: Discussionmentioning

confidence: 99%

Review of the Effects and Mechanism of Curcumin in the Treatment of Inflammatory Bowel Disease

Lin

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Curcumin is extracted from the rhizomes of Curcuma longa L. It is now widely used in food processing, cosmetics, dyes, etc. Current researching indicates that curcumin has high medical value, including anti-inflammatory, antioxidant, anti-tumor, anti-apoptotic, anti-fibrosis, immune regulation and other effects, and can be used to treat a variety of diseases. Inflammatory bowel disease (IBD) is a nonspecific inflammatory disease of the intestine including Crohn’s disease (CD) and ulcerative colitis (UC). The drug treatment effect is often limited and accompanied by side effects. A large number of basic and clinical studies have shown that curcumin has the effect of treating IBD and also can maintain the remission of IBD. In this review, the research of curcumin on IBD in recent years is summarized in order to provide reference for further research and application of curcumin.

show abstract

“…Curcumin has rapid metabolism, chemical instability, high hydrophobicity, and low intestinal absorption, resulting in poor effects in the treatment of UC 27 , 28 . Nanostructured systems have been used to carry a series of drugs with high potential for therapeutic applications.…”

Section: Discussionmentioning

confidence: 99%

Treatment of colitis by oral negatively charged nanostructured curcumin in rats

et al. 2022

View full text Add to dashboard Cite

Purpose: To examine the effects of a negatively charged nanostructured curcumin microemulsion in experimental ulcerative colitis (UC) in rats. Methods: Four percent acetic acid was used to induce UC. The animals were treated for seven days and randomly assigned to four groups: normal control (NC), colitis/normal saline (COL/NS), colitis/curcumin (COL/CUR), and colitis/mesalazine (COL/MES). The nanostructured curcumin was formulated with a negative zeta potential (-16.70 ± 1.66 mV). Dosage of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin 1-β (IL-1β), interleukin 6 (IL-6), and antioxidant enzymes (catalase, superoxide dismutase, and glutathione peroxidase), macro and microscopic evaluation of the colon tissue were analyzed. Results: The COL/CUR group had a higher level of antioxidant enzymes compared to the COL/MESgroup. The levels of TNF-α, IL-1β and IL-6 were significantly lower in the colonic tissue of the COL/CUR group rats, when compared to the COL/NS and COL/MES groups (p < 0.001). The presence of ulcers in the colonic mucosa in rats of the COL/NSgroup was significantly higher than in the COL/MES group (p < 0.001). In the NC and COL/CUR groups, there were no ulcers in the colonic mucosa. Conclusions: The nanostructured microemulsion of curcumin, used orally, positively influenced the results of the treatment of UC in rats. The data also suggests that nanostructured curcumin with negative zeta potential is a promising phytopharmaceutical oral delivery system for UC therapy. Further research needs to be done to better understand the mechanisms of the negatively charged nanostructured curcumin microemulsion in UC therapy.

show abstract

Curcumin ameliorates DSS‑induced colitis in mice by regulating the Treg/Th17 signaling pathway

Cited by 32 publications

References 36 publications

Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook

Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook

Review of the Effects and Mechanism of Curcumin in the Treatment of Inflammatory Bowel Disease

Treatment of colitis by oral negatively charged nanostructured curcumin in rats

Contact Info

Product

Resources

About